Acute Investment Advisory
Acute Investment Advisory reported 17 stocks worth $9M in its 13F filing for Q3 2026, filed Oct 16, 2026. Its largest holdings are EMR (20.7%), SPHY (8.5%) and PGX (8.4%). Compared with Q2 2026, the fund added to AAPL, trimmed SPHY, PGX and VTWO and sold out of LRCX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  EMR Emerson Electric | $1.9M | 20.7% | 12K | No change | 5 of 8 | |
| 2 |  SPHY Spdr Series Trust | $767K | 8.5% | 34K | −833 (−2%) | 3 of 8 | |
| 3 |  PGX Invesco Preferred ETF | $759K | 8.4% | 75K | −1,996 (−3%) | 8 of 8 | |
| 4 |  VTWO Vanguard Scottsdale Fds | $617K | 6.9% | 5,494 | −298 (−5%) | 3 of 8 | |
| 5 |  AAPL Apple Inc | $517K | 5.8% | 1,552 | +20 (+1%) | 8 of 8 | |
| 6 |  QQQM Invesco Nasdaq | $514K | 5.7% | 1,688 | −24 (−1%) | 3 of 8 | |
| 7 |  IVV Ishares TR | $469K | 5.2% | 613 | −21 (−3%) | 3 of 8 | |
| 8 |  SPMB Spdr Series Trust | $467K | 5.2% | 22K | −564 (−2%) | 4 of 8 | |
| 9 |  IWM Ishares TR | $460K | 5.1% | 1,655 | −80 (−5%) | 8 of 8 | |
| 10 |  VGLT Vanguard Scottsdale Fds | $456K | 5.1% | 9,094 | −863 (−9%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 LRCX Lam Research Corp | $217K | 500 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Oct 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Acute Investment Advisory 13F FAQ
What does Acute Investment Advisory own?
Acute Investment Advisory reported 17 stocks worth $9M in its 13F filing for Q3 2026, filed Oct 16, 2026. Its largest holdings are EMR (20.7%), SPHY (8.5%) and PGX (8.4%). The table above lists every position in the filing (the top 10 without an account).
What did Acute Investment Advisory buy and sell in Q3 2026?
Compared with Q2 2026: 0 new positions, 1 added to, 14 trimmed and 1 sold out. It sold all of LRCX.
When will Acute Investment Advisory file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Acute Investment Advisory's portfolio worth?
The Q3 2026 filing reports $9M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.